CSL Behring reports positive AEGIS-I trial results
The AEGIS-I study evaluated the safety and proof of mechanism of CSL112, a novel apolipoprotein A-I (apoA-I) infusion therapy.
CSL112 was designed to help decrease that high risk of early recurrent cardiovascular events that could potentially happen in the weeks up to months following a heart attack. These events are mostly associated with the additional rupture of atherosclerotic plaque that is vulnerable. This type of plaque is the result of fatty material accumulating on the innermost layer of the artery wall that can obstruct blood flow.
"CSL112 may represent an exciting new approach to treating high-risk patients following an acute MI," Harvard Medical School Professor of Medicine and AEGIS-I study co-lead investigator Dr. Michael Gibson said. "By directly targeting and stabilizing plaque very soon after the initial event, CSL112 has the potential to change our current treatment paradigm and improve outcomes for millions of heart attack survivors around the globe."
CSL Behring also reported that the AEGIS-I trial met its main goals, which showed that CSL112 does not significant liver or kidney function changes.